pegylated top1 inhibitor peel-224
Generic: Pegylated TOP1 Inhibitor PEEL-224
pegylated top1 inhibitor peel-224: 1 clinical trial tracked.
pegylated top1 inhibitor peel-224 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about pegylated top1 inhibitor peel-224, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (1)
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Primary endpoint: Maximum Tolerated Dose (MTD) (Phase 1)
Interventionalopen63 targetStarted 2025-01Completion 2029-093 sites · United StatesDavid S Shulman, MD